Market Closed -
Hong Kong S.E.
01:38:22 29/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
4.74
HKD
|
+1.50%
|
|
+16.46%
|
-28.61%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
11,223
|
12,811
|
10,383
|
8,963
|
4,230
|
4,230
|
-
|
Enterprise Value (EV)
1 |
9,585
|
10,969
|
9,089
|
8,240
|
4,994
|
3,681
|
4,025
|
P/E ratio
|
-13.5
x
|
-29.8
x
|
-25.2
x
|
-27.3
x
|
-27.4
x
|
-14.2
x
|
-11.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
71.1
x
|
53.7
x
|
26.6
x
|
17.2
x
|
12.3
x
|
EV / Revenue
|
-
|
-
|
62.2
x
|
49.4
x
|
22.8
x
|
14.9
x
|
11.7
x
|
EV / EBITDA
|
-34.9
x
|
-27.5
x
|
-24.5
x
|
-21.8
x
|
-19.6
x
|
-13.4
x
|
-26
x
|
EV / FCF
|
-24.3
x
|
-25
x
|
-19
x
|
-19.2
x
|
-9.76
x
|
-12.8
x
|
-11.7
x
|
FCF Yield
|
-4.12%
|
-3.99%
|
-5.27%
|
-5.22%
|
-10.2%
|
-7.8%
|
-8.53%
|
Price to Book
|
2.77
x
|
5.64
x
|
5.55
x
|
5.75
x
|
2.78
x
|
3.08
x
|
3.28
x
|
Nbr of stocks (in thousands)
|
8,97,012
|
9,34,939
|
9,36,985
|
9,39,716
|
9,64,844
|
9,64,844
|
-
|
Reference price
2 |
12.51
|
13.70
|
11.08
|
9.538
|
4.384
|
4.384
|
4.384
|
Announcement Date
|
31/03/20
|
23/03/21
|
29/03/22
|
31/03/23
|
28/03/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
146
|
166.8
|
218.8
|
246.3
|
343.7
|
EBITDA
1 |
-274.3
|
-398.3
|
-370.7
|
-377.2
|
-254.2
|
-275.6
|
-154.9
|
EBIT
1 |
-284.7
|
-409.4
|
-415.6
|
-432.4
|
-323.3
|
-308.3
|
-203
|
Operating Margin
|
-
|
-
|
-284.63%
|
-259.15%
|
-147.79%
|
-125.2%
|
-59.05%
|
Earnings before Tax (EBT)
1 |
-832.7
|
-427.8
|
-412.4
|
-325.7
|
-210.6
|
-298.8
|
-377.5
|
Net income
1 |
-832.7
|
-427.8
|
-412.4
|
-325.7
|
-210.6
|
-298.8
|
-377.5
|
Net margin
|
-
|
-
|
-282.44%
|
-195.22%
|
-96.26%
|
-121.33%
|
-109.81%
|
EPS
2 |
-0.9280
|
-0.4600
|
-0.4400
|
-0.3500
|
-0.2200
|
-0.3097
|
-0.3912
|
Free Cash Flow
1 |
-395.2
|
-438
|
-478.7
|
-430
|
-360.4
|
-287.1
|
-343.3
|
FCF margin
|
-
|
-
|
-327.84%
|
-257.7%
|
-161.61%
|
-116.59%
|
-99.87%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
31/03/20
|
23/03/21
|
29/03/22
|
31/03/23
|
28/03/24
|
-
|
-
|
Fiscal Period: December |
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
---|
Net sales
1 |
44.9
|
-
|
146
|
-
|
113.3
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-190.2
|
-270.1
|
-145.5
|
-
|
-
|
Operating Margin
|
-423.73%
|
-
|
-99.67%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-324.7
|
-267.4
|
-145.1
|
-
|
-178.4
|
Net income
1 |
-324.7
|
-267.4
|
-145.1
|
-147.3
|
-178.4
|
Net margin
|
-723.12%
|
-
|
-99.34%
|
-
|
-157.5%
|
EPS
|
-0.3500
|
-0.2900
|
-
|
-0.1600
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23/03/21
|
27/08/21
|
29/03/22
|
31/08/22
|
31/03/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,638
|
1,841
|
1,294
|
724
|
829
|
549
|
206
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-395
|
-438
|
-479
|
-430
|
-360
|
-287
|
-343
|
ROE (net income / shareholders' equity)
|
-77.1%
|
-18.2%
|
-19.9%
|
-19%
|
-13%
|
-19.6%
|
-12.8%
|
ROA (Net income/ Total Assets)
|
-45.2%
|
-15.6%
|
-15.4%
|
-13.5%
|
-9.9%
|
-13.1%
|
-15.2%
|
Assets
1 |
1,841
|
2,747
|
2,672
|
2,411
|
2,127
|
2,276
|
2,485
|
Book Value Per Share
2 |
4.520
|
2.430
|
2.000
|
1.660
|
1.580
|
1.420
|
1.340
|
Cash Flow per Share
2 |
-0.4200
|
-0.3700
|
-0.3400
|
-0.3200
|
-0.3400
|
-0.2600
|
-0.3200
|
Capex
1 |
170
|
90.8
|
158
|
130
|
37.8
|
36.6
|
37.3
|
Capex / Sales
|
-
|
-
|
108.29%
|
77.71%
|
16.94%
|
14.86%
|
10.85%
|
Announcement Date
|
31/03/20
|
23/03/21
|
29/03/22
|
31/03/23
|
28/03/24
|
-
|
-
|
Last Close Price
4.384
CNY Average target price
4.211
CNY Spread / Average Target -3.95% Consensus |
1st Jan change
|
Capi.
|
---|
| -28.61% | 576M | | +2.56% | 42.75B | | +47.70% | 41.61B | | +11.90% | 41.34B | | -8.83% | 26.59B | | +7.11% | 25.49B | | -22.80% | 18.12B | | +30.52% | 12.24B | | -1.92% | 11.76B | | +9.32% | 11B |
Other Biotechnology & Medical Research
|